Nuveen
MRVI icon

Nuveen’s Maravai LifeSciences MRVI Stock Holding History

Nuveen’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8M Buy
2,857,580
+2,627,433
+1,142% +$11.3M ﹤0.01% 1343
2026
Q1 		$651K Buy
230,147
+1,454
+0.6% +$4.93K ﹤0.01% 2749
2025
Q4 		$743K Sell
228,693
-12,488
-5% -$42K ﹤0.01% 2733
2025
Q3 		$692K Hold
241,181
– – ﹤0.01% 2780
2025
Q2 		$581K Sell
241,181
-60,390
-20% -$127K ﹤0.01% 2833
2025
Q1 		$666K Hold
301,571
– – ﹤0.01% 2803
2024
Q4 		$1.64M Hold
301,571
– – ﹤0.01% 2464
2024
Q3 		$2.51M Sell
301,571
-81,108
-21% -$701K ﹤0.01% 2309
2024
Q2 		$2.74M Buy
382,679
+185,000
+94% +$1.6M ﹤0.01% 2225
2024
Q1 		$1.71M Sell
197,679
-53,145
-21% -$360K ﹤0.01% 2466
2023
Q4 		$1.64M Buy
250,824
+14,930
+6% +$96.5K ﹤0.01% 2504
2023
Q3 		$2.36M Sell
235,894
-69,622
-23% -$764K ﹤0.01% 2226
2023
Q2 		$3.8M Buy
305,516
+14,656
+5% +$198K ﹤0.01% 2054
2023
Q1 		$4.08M Sell
290,860
-60,303
-17% -$866K ﹤0.01% 2004
2022
Q4 		$5.03M Buy
351,163
+2,067
+0.6% +$32.5K ﹤0.01% 1900
2022
Q3 		$8.91M Sell
349,096
-16,496
-5% -$414K ﹤0.01% 1550
2022
Q2 		$10.4M Buy
365,592
+4,365
+1% +$138K ﹤0.01% 1479
2022
Q1 		$13.9M Buy
361,227
+14,651
+4% +$491K ﹤0.01% 1428
2021
Q4 		$13.6M Sell
346,576
-143,958
-29% -$5.83M ﹤0.01% 1495
2021
Q3 		$24.1M Buy
490,534
+103,986
+27% +$5.07M 0.01% 1145
2021
Q2 		$16.1M Buy
386,548
+5,860
+2% +$227K ﹤0.01% 1537
2021
Q1 		$13.6M Buy
380,688
+280,688
+281% +$9.3M ﹤0.01% 1604
2020
Q4 		$2.81M Buy
+100,000
New +$2.78M ﹤0.01% 2335

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Nuveen's MRVI Position: Q2 2026 in Review

Nuveen increased its Maravai LifeSciences (MRVI) stake by 1,142% in Q2 2026, buying an estimated $11.3M and bringing the position to 2,857,580 shares worth $17.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1343.

Nuveen first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $24.1M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Nuveen held 2,857,580 shares of Maravai LifeSciences worth $17.8M as of Q2 2026.
  • Nuveen bought 2,627,433 Maravai LifeSciences shares in Q2 2026, an estimated $11.3M.
  • Maravai LifeSciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1343 holding.
  • Nuveen first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Nuveen's Maravai LifeSciences position peaked at $24.1M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.